Analyst Price Targets — MRMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 15, 2022 12:00 am | Kyle Bauser | Colliers Securities | $2.25 | $0.72 | TipRanks Contributor | MariMed Gets Nod to Acquire Cannabis Company; Street Sees 159% Upside |
Latest News for MRMD
NORWOOD, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report its fourth quarter and full year 2025 financial results on March 11, 2026 after the markets close.
Brainsway (NASDAQ: BWAY - Get Free Report) and MariMed (OTCMKTS:MRMD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends. Risk and Volatility Brainsway has a beta of 1.2,
NORWOOD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator committed to improving lives every day, issued the following statement from CEO Jon Levine today.
Veteran and customer of Thrive Dispensary in Anna, IL writes song of appreciation for Thrive and to raise visibility for veteran's org FreedomSingsUSA.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MRMD.
U.S. House Trading
No House trades found for MRMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.